BOLT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

820.80K

-28.06%

-5.518

-34.32%

633.33K

-48.17%

-3.600

-37.93%

-3.520

-21.08%

Estimates Revision

The market is revising Upward the revenue expectations for Bolt Biotherapeutics, Inc. (BOLT) for FY2025, with the revenue forecasts being adjusted by 32.85% over the past three months. During the same period, the stock price has changed by 2.70%.

Revenue Estimates for FY2025

Revise Upward

+32.85%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-5.15%

In Past 3 Month

Stock Price

Go Up

+2.70%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 41.00 USD with a low forecast of 7.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

7.00

Averages

41.00

High

75.00

Current: 0.000

Low

7.00

Averages

41.00

High

75.00

H.C. Wainwright

NULL -> Buy

initiated

2025-10-20

Reason

H.C. Wainwright

Price Target

2025-10-20

initiated

NULL -> Buy

Reason

H.C. Wainwright assumed coverage of Bolt Biotherapeutics with a Buy rating and $7 price target. The company's lead asset, BDC-4182, differentiates itself relative to antibody-drug conjugates since the payload is an immune-stimulatory agent instead of a cytotoxic warhead, the analyst tells investors in a research note. The firm says initial clinical results for BDC-4182 are expected in Q3 of 2026.

Lake Street

Chad Messer

Buy

maintain

$4 -> $75

2025-08-15

Reason

Lake Street

Chad Messer

Price Target

$4 -> $75

2025-08-15

maintain

Buy

Reason

Lake Street analyst Chad Messer raised the firm's price target on Bolt Biotherapeutics to $75 from $4 and keeps a Buy rating on the shares after Bolt ended Q2 with $48.5M in cash and reiterated its cash runway through mid-2026. The company completed a 20:1 reverse stock split to regain compliance with Nasdaq listing requirements in June, notes the analyst, who adjusted the firm's target to account for the reverse split.

Stifel

Stephen Willey

Hold

downgrade

2025-05-13

Reason

Stifel

Stephen Willey

Price Target

2025-05-13

downgrade

Hold

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Bolt Biotherapeutics to $1 from $1.25 and keeps a Hold rating on the shares following management's earnings announcement, corporate update, and review of recently-presented Phase 1 dose-escalation data for BDC-3042. The firm believes ISAC conjugates will likely remain a "show-me" story for investors, the analyst noted.

Stifel

Stephen Willey

Hold

Maintains

$1.5 → $1.25

2025-03-25

Reason

Stifel

Stephen Willey

Price Target

$1.5 → $1.25

2025-03-25

Maintains

Hold

Reason

Stifel lowered the firm's price target on Bolt Biotherapeutics to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of patient enrollment into the Phase 1 single-agent BDC-3042 dose-escalation trial sets the stage for a medical conference presentation in Q2, but the firm continues to believe the competitive intensity of the CLDN18.2 drug development landscape establishes a high safety/efficacy hurdle, the analyst tells investors.

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-25

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-25

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for Bolt Biotherapeutics Inc (BOLT.O) is -0.37, compared to its 5-year average forward P/E of -1.57. For a more detailed relative valuation and DCF analysis to assess Bolt Biotherapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.57

Current PE

-0.37

Overvalued PE

0.67

Undervalued PE

-3.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.61

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.67

Undervalued EV/EBITDA

-3.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

55.66

Current PS

4.18

Overvalued PS

164.71

Undervalued PS

-53.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BOLT News & Events

Events Timeline

No data

News

9.5

2025-11-13NASDAQ.COM

Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements

4.0

2025-10-20Benzinga

HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7

9.0

2025-04-25Newsfilter

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

People Also Watch

Frequently Asked Questions

What is Bolt Biotherapeutics Inc (BOLT) stock price today?

The current price of BOLT is 6.08 USD — it has increased 4.65 % in the last trading day.

What is Bolt Biotherapeutics Inc (BOLT)'s business?

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

What is the price predicton of BOLT Stock?

What is Bolt Biotherapeutics Inc (BOLT)'s revenue for the last quarter?

Bolt Biotherapeutics Inc revenue for the last quarter amounts to 2.17M USD, increased 90.10 % YoY.

What is Bolt Biotherapeutics Inc (BOLT)'s earnings per share (EPS) for the last quarter?

Bolt Biotherapeutics Inc. EPS for the last quarter amounts to -3.72 USD, decreased -53.09 % YoY.

What changes have occurred in the market's expectations for Bolt Biotherapeutics Inc (BOLT)'s fundamentals?

How many employees does Bolt Biotherapeutics Inc (BOLT). have?

Bolt Biotherapeutics Inc (BOLT) has 52 emplpoyees as of January 09 2026.

What is Bolt Biotherapeutics Inc (BOLT) market cap?

Today BOLT has the market capitalization of 11.15M USD.